Results 201 to 210 of about 32,890 (266)

The unintended consequences of the inflation reduction act on biosimilar market incentives and Medicare savings. [PDF]

Health Aff Sch
Beinfeld MT, Ghule P, LaMountain F, Wong W, Ko S, Chambers JD.   +5 more
europepmc   +1 more source

Disseminated peritoneal coccidioidomycosis mimicking malignancy in an immunosuppressed patient: a case report. [PDF]

J Surg Case Rep
Meyer R, Bresler T, Palmer K, Kademian M.   +3 more
europepmc   +1 more source

Comparative Safety of Advanced Therapies for Crohn Disease. [PDF]

JAMA Netw Open
Park SK, Ahuja D, Yeh KH, Patel SB, Goodwin SW, Ma C, Singh N, Ananthakrishnan AN, Jairath V, Xu R, Singh S.   +10 more
europepmc   +1 more source

Comparative risk of serious infection among biologic therapies for inflammatory bowel disease in pediatric patients: A target trial emulation. [PDF]

J Pediatr Gastroenterol Nutr
Tsai SY, Ananthakrishnan AN, Winter HS, Ma KS.   +3 more
europepmc   +1 more source

The efficacy of ustekinumab in the management of perianal fistulizing Crohn's disease. [PDF]

Intest Res
Moon HS.
europepmc   +1 more source

One-year single-center follow-up study of ustekinumab and vedolizumab use in inflammatory bowel disease Egyptian patients as second-line therapy after anti-TNF failure. [PDF]

Prz Gastroenterol
Kamel S, Alaty WHA, Rashad H, Fathy D, Abdel-Samiee M, Hindy I, Shaban A, Askar S.   +7 more
europepmc   +1 more source

Balancing Act: Lessons From Comanaging Patients With Inflammatory Bowel Disease and HIV/AIDS. [PDF]

ACG Case Rep J
Cruz Grave E, Paik P, Kim J, Odufalu FD.
europepmc   +1 more source

Efficacy and safety of IL-23p19 and IL-12/23p40 inhibitors in moderate-to-severe Crohn's disease: a systematic review and network meta-analysis. [PDF]

Ann Med
Kaneko M, Sakuraba A.
europepmc   +1 more source

Ustekinumab may have therapeutic effects on autoimmune thyroid disease. [PDF]

Sci Rep
Guzel SS, Demir AN, Eskazan T, Hatemi AI, Gonen MS.   +4 more
europepmc   +1 more source

A 17-Year-Old Male Adolescent With Refractory Crohn's Disease Managed With Upadacitinib and Risankizumab Combination Therapy: A Case Report and Review of Current Evidence. [PDF]

Am J Case Rep
Alhashemi M, Shehab M.
europepmc   +1 more source